(OAKVILLE, Ontario) June 11, 2026 ­– FORUS Therapeutics Inc (“FORUS”) is pleased to announce that it has been acquired by PharmaEssentia Corporation, a global biopharmaceutical company focused on developing innovative therapies for hematology, oncology, and...

We are pleased to announce that Marie-Josèphe Champagne has returned to FORUS as Senior Medical Science Liaison (MSL) for Quebec and Atlantic. Marie-Josèphe brings extensive experience from her recent role as National MSL Manager for Hematology, along with more than a...

FORUS Therapeutics Inc. is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Quebec as of November 6th. Further details on the criteria can be found in the links below: Liste des médicaments - Établissement - en vigueur le 6 novembre 2025 Liste...